7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Inclusion Criteria: * Subjects with documented disaccharidase assay levels of lactase, sucrase, maltase, and palatinase via EGD disaccharidase assay (DA) performed no more than 1 year prior to enrollment with normal histological interpretation. Eligible subjects will be enrolled into the following study groups based on their documented sucrase level. * DA Sucrase \< 25 (n=500) * DA Sucrase 25-35 (n=500) * DA Sucrase \>55 (n=100) * At the discretion of the investigator, subject is suspected of CSID and has at least one symptom of diarrhea, abdominal pain, gas/bloating, nausea, or borborygmi at least 3x per week for the past 3 months or more. * Subject or parent/guardian must provide informed consent/assent prior to any study procedures being performed. * Subject is a U.S. resident. * Subject is male or female, ages 6 months to 17 years old. * Subject/parent or guardian is willing and able to complete necessary study procedures including following study instructions, completing electronic questionnaires via a personal mobile device, attending study visits and, in the Investigator's judgment, is sufficiently stable to participate in the study. * Subject/ parent or guardian must be able to read or understand the English language. * Subject or parent/guardian must have their own Android or Apple device for BYOD. Exclusion Criteria: * Females who are lactating or pregnant. * Subjects with allergy to sucrose, yeast, papain, or glycerol. * Subjects with causes of abdominal pain or altered bowel habits other than CSID such as inflammatory bowel disease, celiac disease, eosinophilic gastrointestinal disorder, pancreatitis, or gastrointestinal bleeding. * Subjects with a history of diabetes mellitus. * Subjects with a recent febrile illness (5 days prior to study). * Subjects that do not have the mental capacity to understand the study requirements and are unable to comply. * Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial. * Subject has previously used Sucraid®. * Subject has uncontrolled systematic disease.